Select Language

FGF-21

FGF-21 Overview

English Name	Fibroblast growth factor 21	Approved Drugs	0
Drugs in Clinical Trials	10	Target Synonym	FGF21
Highest Development Stage	Phase 3 Clinical

English Name	Fibroblast growth factor 21
Target Synonym	FGF21
Approved Drugs	0
Drugs in Clinical Trials	10
Highest Development Stage	Phase 3 Clinical

FGF-21 Product List

Product Category
Protein (2)Cell (1)Kits (1)
Product Status
Launched (4)
Species
Human (4)
Tag
His Tag (1)His Tag & Avi Tag (1)- (2)
Conjugate
Unconjugated (1)Biotin-labeled (1)- (2)

Cat. No.	Species	Host	Product Description
HOT FG1-H5243	Human	HEK293	Human FGF-21 Protein, His Tag (SPR verified)
CEA-B268	Human	-	Human FGF-21 ELISA Kit
CHEK-ATF163	Human	HEK293	Human FGF-21 (Luc) HEK293 Reporter Cell
FG1-H82Q3	Human	HEK293	Biotinylated Human FGF-21 Protein, His,Avitag™

Total: 4

FGF-21 Background

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

FGF-21 Synonyms

FGF-21, FGF21

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Pegozafermin	BIO89-100; TEV-47948	Phase 3 Clinical	Teva Pharmaceutical Industries Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
Efimosfermin alfa	LLF-580; BOS-580; GSK-6519754	Phase 3 Clinical	Novartis Pharma Ag	Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
Efruxifermin	AKR-001; AMG-876; EFX; Fc-FGF21(RGE)	Phase 3 Clinical	Amgen Inc	Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
MWN-105	MWN-105	Phase 2 Clinical	Shanghai Minwei Biotechnology Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	Details
TQA-2225	AP-025; TQA2225; TQA-2225	Phase 2 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
HEC-88473	HEC-88473; HEC88473; APL-18881	Phase 2 Clinical	Dongguan Hec Taigen Biopharmaceuticals Co Ltd	Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
B-1344	B-1344	Phase 1 Clinical	Tasly Biomedical Co Ltd	Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
DMR-2301	DMR-2301; DMR2301	Phase 1 Clinical	Shanghai Duomirui Biotechnology Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
ZT-003	ZT003; ZT-003	Phase 1 Clinical	Beijing QL Biopharmaceutical Co Ltd	Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
AP-026	TQA2226; AP026; AP-026; TQA-2226	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	Details